Cutaneous, pulmonary and bone aspergillosis in a patient presumed immunocompetent presenting subacute cutaneous lupus erythematosus;Aspergillose cutanée, pulmonaire et osseuse chez un malade ayant un lupus érythémateux cutané subaigu sans déficit immunitaire associé

Annales de Dermatologie et de Venereologie

Volumn 135, Issue 3, 2008, Pages 217-221

  Domergue, V ^a   Orlandini, V ^a   Begueret, H ^a   Couprie, B ^b   Huerre, M ^c   Tunon de Lara, M ^a   Beylot Barry, M ^a   Doutre, M S ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Aspergillosis; Lupus erythematosus

Indexed keywords

CASPOFUNGIN; THALIDOMIDE; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NODULE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; BONE DISEASES, INFECTIOUS; ECHINOCANDINS; HUMANS; LUNG; LUNG DISEASES, FUNGAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PYRIMIDINES; SKIN; TREATMENT OUTCOME; TRIAZOLES;

EID: 43149086105     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2007.04.009     Document Type: Article

References (22)

1. Denning D.W. Invasive aspergillosis. Clin Infect Dis 26 (1998) 781-805
2. Levitz S.M. Overview of host defenses in fungal infections. Clin Infect Dis 14 Suppl. 1 (1992) S37-S42
3. Milpied N. Diagnostic des infections fongiques en oncohématologie. Réanimation en oncohématologie (2004), Elsevier, Paris pp : 332-51
4. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestermann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
5. Kirkpatrick W.R., Perea S., Coco B.J., Patterson T.F., Bennett J.E., Greene R.E., et al. Efficacy of capsofungine alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 46 (2002) 2564-2568
6. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., Dupont B., De la Torre-Cisneros J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36 (2003) 1122-1131
7. Mouas H., Lutsar I., Dupont B., Fain O., Herbrecht R., Lescure F.X., et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 40 (2005) 1141-1147
8. Franks M.E., Macpherson G.R., and Figg W.D. Thalidomide. Lancet 363 (2004) 1802-1811
9. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 (1993) 1675-1680
10. Mchug S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M., et al. The immunosuppressive drug thalidomide induces T helper cells 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99 (1995) 160-167
11. Cenci E., Perito S., Enssle K., Mosci P., Latge J.P., Romani L., et al. TH1 and TH2 cytokines in mice with invasive aspergillosis. Infect Immun 65 (1997) 564-570
12. Nagai H., Guo J., Choi H., and Kurup V. Interferon γ and tumor necrosis factor-α protect mice from invasive aspergillosis. J Infect Dis 172 (1995) 1554-1560
13. Curley M.J., Hussein S.A., and Hassoun P.M. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol 40 (2002) 2302-2304
14. Wölfer A., Bauer F., Zollner G., Weber K., Sill H., and Linkesch W. Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma. Haematologica 88 (2004) 12
15. Stanzani M., Orciuolo E., Lewis R., Kontoyiannis D.P., Martins S.L., St John L.S., et al. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood 105 (2005) 2258-2265
16. Orem J., Mpanga L., Habyara E., Nambuya A., Aisu T., Wamukota W., et al. Disseminated aspergillus fumigatus infection: case report. East Afr Med J 75 (1998) 436-438
17. Khatri M.L., Stefanato C.M., Benghazeil M., Shafi M., and Kubba A. Cutaneous and paranasal aspergillosis in an immunocompetent patient. Int J Dermatol 39 (2000) 853-856
18. Javier R.M., Sibilia J., Lugger A.S., Natarajan-Ame S., Kuntz J.L., and Herbrecht R. Fatal Aspergillus fumigatus myositis in an immunocompetent patient. Eur J Clin Microbiol Infect Dis 20 (2001) 810-813
19. Ribeiro S.C., Santana A.N., Arriagada G.H., Martins J.E., and Takagaki T.Y. A novel cause of invasive pulmonary infection in an immunocompetent patient: aspergillus candidus. J Infect 51 (2005) e195-e197
20. Mohan A., Guleria R., Mukhopadhyaya S., Das C., Nayak A., and Sharma S.K. Invasive tracheobronchial aspergillosis in an immunocompetent person. Am J Med Sci 329 (2005) 107-109
21. Garcia R.J., Troya P., and Edwards C. Invasive aspergillosis with central nervous system dissemination in a presumably immunocompetent, non neutropenic patient: case report and review. South Med J 99 (2006) 607-610
22. Donoso F.A., Camacho A.J., Alarcon L.P., and Cruces R.P. Aspergilosis invasora multisistemica en un nino inmunocompetente: comunicacion de un caso. Rev Chil Infectol 23 (2006) 69-72